Test Price
4,800 AEDโ Home Collection Available
HLA DSA-SAB Class II IgG Antibodies with C1q Screen Test in UAE | 4800 AED | DHA-Licensed Laboratory
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity โ ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139)
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test consultation with a specialist for result interpretation โ direct access to physician insights.
Insurance: Direct billing verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
The HLA DSA-SAB Class II IgG Antibodies with C1q Screen is a high-resolution Luminex-based single antigen bead (SAB) assay designed to detect donor-specific IgG antibodies against HLA class II (DR, DQ, DP) and assess their complement-fixing capacity via C1q binding. This test is indispensable for pre-transplant immunologic risk assessment, post-transplant antibody-mediated rejection (AMR) monitoring, and guiding immunosuppressive strategies.
| Feature | Our Test (C1q-Screened Luminex) | Standard HLA Class II IgG SAB (No C1q) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity & C1q Binding Specificity | ~95% Sensitivity; no functional complement data |
| Methodology | Luminex X-Mapยฎ Single Antigen Bead + C1q Assay | Luminex IgG SAB only |
| Turnaround | 10-12 Days (Cold-Chain Logistics) | 14-16 Days |
Physician Insight & Safety Protocols
โAs a General Practitioner, I advise that this test provides powerful data on donor-specific antibody activity. However, results must be integrated with clinical assessment and biopsy findings. Never alter immunosuppressive therapy without direct transplant specialist consultation, as this could lead to graft rejection. Seek immediate medical attention if you notice sudden oliguria, graft tenderness, or unexplained fever.โ
โ Dr. Ajay Singh (DHA License: 36234132)
Medication Warning
Do not discontinue prescribed immunosuppressants or other maintenance therapy without consulting your treating physician. Altering your medication regimen may precipitate acute rejection or life-threatening complications.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection or sepsis; recent live-virus vaccination (within 4 weeks) may cause false-positive C1q binding; known current acute rejection episode under active treatment.
- ER Red Flags: Sudden decrease in urine output (<500 mL/day in adults), severe hypertension refractory to medication, acute graft tenderness with fever, or signs of graft infarction โ seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the C1q-binding assay in determining transplant risk?
The C1q-binding assay identifies complement-fixing donor-specific HLA antibodies, which are strongly associated with antibody-mediated rejection and graft loss, enabling early risk stratification before clinical symptoms appear. By focusing on complement-activating DSA, nephrologists can preemptively adjust immunosuppression, potentially preventing irreversible graft damage.
2. Why is home collection available for this and how is sample integrity maintained?
Home collection is performed by licensed phlebotomists using validated cold-chain protocols that maintain serum stability from venipuncture to laboratory processing, preserving antibody integrity and preventing complement degradation. Samples are transported in temperature-monitored containers directly to our ISO-certified facility, meeting UAE PDPL and cold-chain compliance standards.
3. Does health insurance cover the 4800 AED cost for HLA DSA testing?
Most UAE insurers cover HLA DSA testing when medically necessary for transplant monitoring; direct billing verification via WhatsApp +971 54 548 8731 ensures pre-authorization and minimizes out-of-pocket expenses. Our team can assist with insurance clearance within 24 hours, in accordance with UAE PDPL data privacy requirements.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA) Facility License No. 1143. All personal health data is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Sample handling and patient consent follow the standards set forth in Federal Decree-Law No. 4 of 2016 on Medical Liability. Your data is encrypted and accessible only to authorized medical personnel.
Clinical & Logistical Metadata
| Test Name | HLA DSA-SAB Class II IgG Antibodies with C1q Screen |
| Price (AED) | 4,800 |
| Turnaround Time | 10-12 Business Days |
| Sample Type / Matrix | Serum (peripheral blood) |
| Methodology Used | Luminex X-Mapยฎ Single Antigen Bead + C1q Assay |
| ICD-10-CM Code | Z94.0 (Kidney transplant status) |
| LOINC Code | 93336-2 |
| DHA Facility License & Laboratory Address | License No. 1143 โ DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians